Approved indication: Miebo (perfluorohexyloctane ophthalmic solution) is FDA-approved to treat the signs and symptoms of dry eye disease in adults.

Who may benefit most: It is especially useful for people whose dry eye is driven by excess tear evaporation, often linked to meibomian gland dysfunction, and is commonly chosen when symptoms persist despite artificial tears and basic dry-eye measures.

Off-label uses: There are no well-established off-label uses; clinicians primarily use Miebo within its approved role for dry eye disease, focusing on patients with prominent evaporative symptoms.

Efficacy expectations:

• In clinical studies, many patients had noticeable improvement in dryness symptoms and surface damage within about 2 weeks, with further improvement by 8 weeks and with continued use.
• Miebo improved both objective signs (such as corneal staining) and patient-reported symptoms compared with saline eye drops.
• Compared with other prescription dry-eye therapies that mainly reduce inflammation or increase tear production, Miebo is unique in directly reducing tear evaporation and is often combined with lid hygiene and, when needed, other dry-eye medications for a more complete treatment plan.

Typical dose and how to use:

• Adults are usually instructed to instill one drop of Miebo into each affected eye four times a day (for example, morning, midday, evening, and bedtime), or exactly as prescribed.
• Wash your hands, tilt your head back, gently pull down the lower eyelid to create a small pocket, hold the bottle above the eye without touching it to the eye or lashes, and squeeze out a single drop.
• Remove contact lenses before using Miebo and wait at least 30 minutes after each dose before putting them back in.

Using with other eye drops: If you use other prescription or over-the-counter eye drops, your eye doctor may advise spacing them by several minutes and often using Miebo last so that other drops do not wash it away.

Special dosing instructions:

• Use Miebo consistently every day as directed; each bottle is designed to provide about a one-month supply at the usual dosing schedule.
• Follow the bottle-priming and squeezing steps in the instructions so you reliably get one small drop each time.

Missed dose: If you miss a dose, apply one drop as soon as you remember unless it is almost time for your next scheduled dose; if so, skip the missed dose and resume your regular schedule without using extra drops.

Overdose: Applying more drops than prescribed is unlikely to cause serious problems, but if a large amount is used or swallowed, or if you develop persistent eye pain, severe irritation, or vision changes, contact your eye doctor, poison control center, or emergency services for advice.

Common side effects:

• Mild, temporary blurred vision right after putting in the drop (reported in about 1%–3% of users), sometimes with slight eye redness or irritation.
• Occasional brief burning or stinging when the drop is instilled; this usually resolves quickly and does not require stopping the medicine.

Serious or rare adverse effects (seek medical help right away):

• Signs of an allergic reaction in or around the eye, such as severe redness, swelling, rash, or intense itching.
• Sudden or severe eye pain, marked vision changes, or symptoms suggesting an eye infection, such as increasing redness, discharge, or strong light sensitivity.

Warnings and precautions:

• Contact lenses: Remove lenses before using Miebo and wait at least 30 minutes before reinserting them.
• Age: Safety and effectiveness have not been established in children under 18 years.
• Pregnancy and breastfeeding: Human data are limited; because very little drug enters the bloodstream, risk is thought to be low, but use only after discussing potential benefits and uncertainties with your clinician.
• Kidney or liver disease: No specific dose adjustment is usually needed due to minimal systemic absorption, but all medical conditions should be reviewed with your prescriber.
• Allergy: Do not use Miebo if you have had a hypersensitivity reaction to perfluorohexyloctane or any component of the drops.

Relative safety profile: In clinical trials, no serious treatment-related ocular side effects were observed, discontinuations due to side effects were rare, and overall tolerability was favorable compared with many other prescription dry-eye treatments.

Reporting side effects and updates: Side effects can be reported to the FDA MedWatch program (1-800-FDA-1088) or to the manufacturer, and updated safety information is available from your pharmacist, prescriber, or the FDA website.

Drug and product interactions:

• No specific drug–drug interactions have been identified for Miebo, and systemic absorption from the eye is very low.
• Miebo can generally be used along with other eye drops (such as artificial tears or glaucoma drops), but they are usually given at different times; many clinicians prefer Miebo to be instilled last so other drops do not wash it away.
• There are no known interactions with foods, beverages, or alcohol.
• Do not administer Miebo while wearing contact lenses; remove lenses before dosing and wait at least 30 minutes before reinserting them.

Conditions and co-medications requiring caution:

• History of allergy or hypersensitivity to perfluorohexyloctane or similar products.
• Active eye infection, recent eye surgery, or significant eye injury, which may require timing or treatment adjustments determined by your eye doctor.
• Pregnancy, plans for pregnancy, or breastfeeding, because human data are limited even though systemic exposure is expected to be minimal.

Monitoring needs: No routine blood tests or heart monitoring are required; ongoing follow-up consists mainly of regular eye examinations and symptom review with your eye care professional to assess benefit and tolerability.

Q: What is Miebo and what is it used for?
A: Miebo is a prescription eye drop containing perfluorohexyloctane that is used to treat the signs and symptoms of dry eye disease, especially when excess tear evaporation plays a major role.

Q: How long does it take for Miebo to start working?
A: Some people notice improvement in eye dryness and comfort within about 2 weeks, but full benefit often continues to build over 8 weeks or longer with regular use.

Q: Can I use Miebo with my contact lenses?
A: You should remove contact lenses before putting in Miebo and wait at least 30 minutes after each dose before reinserting them.

Q: Can I use artificial tears or other eye drops along with Miebo?
A: Yes, many patients use Miebo together with artificial tears or other prescription eye drops, but these are usually spaced out and Miebo is often used last; ask your eye doctor for a schedule that fits your regimen.

Q: Is Miebo safe to use long term?
A: Clinical studies and extension studies show Miebo is generally well tolerated with low rates of side effects or discontinuation, and it is intended for ongoing use in chronic dry eye under your doctor’s supervision.

Q: Can children use Miebo?
A: Miebo has not been studied enough in children under 18 years, so its safety and effectiveness in this age group are not established and pediatric use should be decided by a specialist.

Storage: Store Miebo at room temperature (59°F to 77°F / 15°C to 25°C), keep the bottle tightly closed, protect it from extreme heat, and keep it out of reach of children and pets.

After opening: You may use the bottle until the expiration date printed on the label as long as it is stored correctly and the solution stays clear and uncontaminated.

Disposal: Do not pour leftover drops down the sink or toilet; when the bottle is empty, expired, or no longer needed, discard it in household trash or follow your pharmacist’s or local community’s medicine take-back or safe-disposal instructions.